Visit us at Booth #104 at PEGS Europe in Lisbon, Portugal.
Accelerate Kinetic Screening and Epitope Characterization of Antibody Libraries with Array SPR
Presenter: Yasmina Noubia Abdiche, PhD, Chief Scientific Officer, Carterra
Date: Wednesday, 14 November
Times: 10:35 – 11:15, 15:35 – 16:15, and 17:45 – 18:45
Throughput, speed, resolution, and sample consumption are typically key limiting factors for performing detailed kinetic and epitope characterization of monoclonal antibody (mAb) libraries destined for use as therapeutics. In addition, mAb immune responses can be used to survey the epitope landscape of pathogens and inform the design of more effective immunogens for vaccines. We demonstrate three core applications of Array SPR: capture kinetics, epitope binning, and epitope mapping, that together provide a comprehensive characterization of your mAb library with minimal sample consumption, enabling more confident decisions to be made earlier in the research process and obviating the need for preliminary ELISA screening. We show that Array SPR can facilitate the generation of high quality kinetic data from 384 mAbs in parallel, using < 1 µg per mAb and only 2 µg of antigen. Epitope binning in a 384-mAb array format allows for a rapid assessment of the depth and breadth of your library’s epitope diversity, providing exquisite resolution between near-identical clones, using < 5 µg per mAb and about 100 µg antigen. Finally, a large panel of mAbs can be mapped against a 384-peptide library, if their epitopes can be (partially) recapitulated on peptides, using 1 µg per mAb and < 0.1 µg per peptide.
Naturally Optimized Human Antibodies from the OmniChicken™ Platform
Presenter: Phil Leighton, PhD, Director of Molecular Biology, Ligand Pharmaceuticals
Date: Thursday, 15 November
Time: 12:15 – 12:45
Because of their phylogenetic distance from humans, chickens recognize a wider range of epitopes on human targets than mammalian hosts, can deliver cross-reactive antibodies for pre-clinical studies that obviate the need for surrogate antibodies, and recognize highly conserved human proteins that may not be immunogenic in mammals. The OmniChicken™ has been engineered to express an immune response consisting of human antibodies and represents a next-generation technology for the discovery of monoclonal antibody therapeutic candidates.